Back
Emergent BioSolutions 10K Form
Sell
14
EBS
Emergent BioSolutions
Last Price:
$5.71
Seasonality Move:
5.31%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-02 | 10Q | EBS/Emergent BioSolutions Quarterly |
2023-12-11 | 10Q | EBS/Emergent BioSolutions Quarterly |
2023-08-09 | 10Q | EBS/Emergent BioSolutions Quarterly |
2023-05-10 | 10Q | EBS/Emergent BioSolutions Quarterly |
2022-11-09 | 10Q | EBS/Emergent BioSolutions Quarterly |
2022-08-02 | 10Q | EBS/Emergent BioSolutions Quarterly |
Receive EBS News And Ratings
See the #1 stock for the next 7 days that we like better than EBS
EBS Financial Statistics
Sales & Book Value
Annual Sales: | $1B |
---|---|
Cash Flow: | $-81.6M |
Price / Cash Flow: | 8.56 |
Annual Sales: | $8.89 |
Price / Book: | 0.64 |
Profitability
EPS (TTM): | -3.73000 |
---|---|
Net Income (TTM): | $-190.6M |
Gross Margin: | $332.3M |
Return on Equity: | -35.42% |
Return on Assets: | -11.9% |
Emergent BioSolutions Earnings Forecast
Key Emergent BioSolutions Financial Ratios
-
The Gross Profit Margin over the past 23 years for EBS is 32.78%.
-
The Selling, General & Administrative Expenses for EBS have been equal to 30.39% of Gross Profit Margin.
-
The Research & Development expenses have been 6.98% of Revenue.
-
The Net Earning history of EBS is -18.80% of Total Revenues.
-
Per Share Earnings over the last 24 years have been positive in 13 years.
Emergent BioSolutions Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | EBS |
CUSIP: | 29089Q |
Website: | emergentbiosolutions.com |
Debt
Debt-to-Equity Ratio: | 1.37 |
---|---|
Current Ratio: | 3.69 |
Quick Ratio: | 1.56 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 3.75 |
EBS Technical Analysis vs Fundamental Analysis
Sell
14
Emergent BioSolutions (EBS)
is a Sell
Is Emergent BioSolutions a Buy or a Sell?
-
Emergent BioSolutions stock is rated a SellThe current Emergent BioSolutions [EBS] share price is $5.71. The Score for EBS is 14, which is 72% below its historic median score of 50, and infers higher risk than normal.